Publications

Search our bibliography using the filters on the right-hand side.

Displaying 101 through 150 of 2394 publications.

Paret K, Beyhaghi H, Herring WL, Mauskopf J, Shane LG, Rousculp WD. Going forward: potential impact of protein-based COVID-19 vaccination coverage on population outcomes and costs in the United States. Vaccines (Basel). 2024 Jan 12;12(1):74. doi: 10.3390/vaccines12010074

Teittson S, Brodtkorb T-H, Kurt M, Patel M, Poretta T, Knight C, Kamgar F, Palmer S. Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo. J Med Econ. 2024 Jan;27(1):473-81. doi: 10.1080/13696998.2024.2322394

Curran D, Patterson BJ, Carrico J, Salem A, La EM, Lorenc Stephane, Hicks KA, Poston S, Carpenter CF. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. Hum Vaccin Immunother. 2023 Dec 31;19(1):2167907. doi: 10.1080/21645515.2023.2167907

Golden AH, Gabriel MH, Russo J, Price M, Ruhmel S, Nilsson A, Delong PS, Jelsma J, Carty M. Let's talk about it: an exploration of the comparative use of three different digital platforms to gather patient-reported outcome measures. J Patient Rep Outcomes. 2023 Dec 12;7(1):130. doi: 10.1186/s41687-023-00666-9

Escobar MA, Fan QA, Mokdad AG, Tarantino MD, Burgess B, Hawe E, Fernandez M, Bullano M. Clinical outcomes of noninhibitor patients with hemophilia a switching from prophylaxis with factor VIII to emicizumab: a meta-analysis of real-world evidence studies. Presented at the 65th ASH Annual Meeting & Exposition 2023; December 9, 2023. San Diego, CA.

Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D. Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer unselected for DDR mutations. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S149. doi: 10.1016/j.jval.2023.09.772

Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D. Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer with HRR mutations. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S119. doi: 10.1016/j.jval.2023.09.772

Spelman T, Herring WL, Acosta C, Hyde R, Jokubaitis VG, Pucci E, Lugaresi A, Laureys G, Havrdova EK, Horakova D, Eichau S, Ozakbas S, Alroughani R, Kalincik T, Duquette P, Girard M, Petersen T, Patti F, Csepany T, Granella F, Grand'Maison F, Ferraro D, Karabudak R, Jose Sa M, Trojano M, Van Pesch V, Van Mijmeersch B, Cartechini E, McCombe P, Gerlach O, Spitaleri D, Rozsa C, Hodgkinson S, Bergamaschi R, Gouider R, Soysal A, Castillo-Trivino T, Prevost J, Garber J, de Gans K, Ampapa R, Simo M, Sanchez-Menoyo JL, Iuliano G, Sas A, van der Walt A, John N, Gray O, Hughes S, De Luca G, Izquierdo G, Onofrj M, Buzzard K, Skibina O, Terzi M, Slee M, Solaro C, Oreja-Guevara C, Ramo-Tello C, Fragoso Y, Shaygannejad V, Moore F, Rajda C, Aguera Morales E, Butzkueven H. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. J Med Econ. 2023 Dec;27(1):109-25. doi: 10.1080/13696998.2023.2293379

Krause T, Fleming A, Hurst M, Zema C, Costello J, Hawe E, Ling C. Prognostic factors and surrogate endpoints in obstructive hypertrophic cardiomyopathy: a systematic literature review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S36. doi: 10.1016/j.jval.2023.09.189

Houghton K, Nangia A, Hawe E. Use of external control arms (ECAs) in marketing applications submitted to European medicines agency (EMA): a targeted review. Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S404. doi: 10.1016/j.jval.2023.09.2119

Drummond MF, Augustovski F, Bhattacharyya D, Campbell J, Chaiyakunapruk N, Chen Y, Galindo-Suarez RM, Guerino J, Mejia A, Mujoomdar M, Ollendorf D, Ronquest N, Torbica A, Tsiao E, Watkins J, Yeung K, ISPOR HTA Council Working Group on HTA in Pluralistic Healthcare Systems collaborators. Corrigendum to Challenges of health technology assessment in pluralistic healthcare systems: an ISPOR Council Report: [Value in Health 25 (2022) 1257-1267/3488]. Value Health. 2023 Dec;26(12):1811. doi: 10.1016/j.jval.2023.06.010

Nangia A, Houghton K, Hawe E. Use of external control arms in pharmaceutical submissions to the national institute for health and care excellence for technology appraisals: a targeted review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S416. doi: 10.1016/j.jval.2023.09.2180

Cook C, Carrico J, Talbird S, Sabale U, Dolk C, Bencina G. Public health impact of the pediatric immunization program in the Netherlands. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S135-6. doi: 10.1016/j.jval.2023.09.705

Hawe E, Simou E, Balp MM, Kohli R, Wiyani A. Influence of disease activity and angioedema on EQ-5D-5L utility scores in chronic spontaneous urticaria. Poster presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S500. doi: 10.1016/j.jval.2023.09.2697

Stirnadel-Farrant HA, Xu X, Kwiatek J, Jain P, Meyers J, Candrilli S, Mines D, Datto CJ. Characteristics, treatment patterns, healthcare resource utilization and costs in patients with bullous pemphigoid: a retrospective analysis of US health insurance claims data. J Am Acad Dermatol. 2023 Dec;13:117-25. doi: 10.1016/j.jdin.2023.04.014

Handels R, Herring W, Kamgar F, Gustavsson A, Skoldunger A, Wimo A, Tate A, Winblad B, Stellick CB, Bruck C, Green C, de Kok I, Hlavka J, Mar J, Urbich M, Soto-Gordoa M, Pemberton-Ross P, Aye S, Jonsson L, workshop 2023 Participants I. IPECAD modeling workshop 2023 cross comparison challenge on cost-effectiveness models in Alzheimer's disease and related dementias. Poster presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S419. doi: 10.1016/j.jval.2023.09.2194

Mellott CE, Jaworski R, Carrico J, Talbird SE, Dobrowolska I, Golicki D, Bencina G, Clinkscales M, Karamousouli E, Eiden AL, Sabale U. Public health impact and return on investment of the pediatric immunization program in Poland. Expert Rev Vaccines. 2023 Dec;22(11):1114-25. doi: 10.1080/14760584.2023.2275712

Goyal RK, Candrilli SD, Abughosh SM, Chen H, Holmes HM, Johnson ML. Social Determinants of Health (SDoH) and other predictors in treatment initiation with CDK4/6 inhibitors in Medicare patients with HR+/HER2– Metastatic Breast Cancer (MBC). Poster presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S286. doi: 10.1016/j.jval.2023.09.1502

Vickers A, Leng X. The impact of life expectancy exclusion criteria on survival curve extrapolation. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S406. doi: 10.1016/j.jval.2023.09.2131

Vickers A. The performance of anchored and unanchored population adjustment methods (matching-adjusted indirect comparison, simulated treatment comparison, and multiple imputation marginalization) in castration resistant prostate cancer. Poster presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S400-1. doi: 10.1016/j.jval.2023.09.2098

Hartley L, Gildea L, Mordin M, Long J, D'Souza V, Kinderås M, Ling C, Warttig S. Does real-world evidence play a role in decision-making by HTA bodies for medical technologies? Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S434-5. doi: 10.1016/j.jval.2023.09.2271

Ronquest N, Paret K, Mladsi DM, Lee LJ. Exploring the value of country-specific cost-effectiveness models in early stages of drug development. Poster presented at the ISPOR Europe 2023; November 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S94. doi: 10.1016/j.jval.2023.09.493

Jen MH, Kiiskinen U, Khanal M, Han Y, Hess L, Tian W, Vickers A. Matching Adjusted Indirect Comparison (MAIC) of selpercatinib Vs cabozantinib in RET mutation-positive advanced Medullary Thyroid Cancer (MTC). Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S18. doi: 10.1016/j.jval.2023.09.094

Cadarette S, Rementeria MA, Espinosa EG, Stewart F, Brisibe T, Devani D, Kistler K, Oladapo T, Rangi ND, Wissinger E. Quality of life (QOL) instruments used in clinicaltrials.gov-indexed trials of gene-modified cell therapy (GMCT) in patients with multiple myeloma (MM). Poster presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S495. doi: 10.1016/j.jval.2023.09.2676

Melgar M, Abrams JY, Godfred-Cato S, Shah AB, Garg A, Strunk A, Narasimhan M, Koptyev J, Norden A, Musheyev D, Rashid F, Tannenbaum R, Estrada-Y-Martin RM, Patel B, Karanth S, Achenbach CJ, Hall GT, Hockney SM, Caputo M, Abbo LM, Beauchamps L, Morris SB, Cifuentes RO, de St Maurice A, Bell DS, Prabaker KK, Sanz Vidorreta FJ, Bryant E, Cohen DK, Mohan R, Libby CP, SooHoo S, Domingo TJ, Campbell AP, Belay ED. A multicenter retrospective cohort study to characterize patients hospitalized with MIS-A and COVID-19 in the United States, 2020-2021. Clin Infect Dis. 2023 Nov 17;77(10):1395-405. doi: 10.1093/cid/ciad374

Goyal RK, Zhang J, Davis KL, Sluga-O'Callaghan M, Kaufman PA. Early real-world treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with eribulin after prior immuno-oncology or antibody–drug conjugate therapy. Clin Breast Cancer. 2023 Nov 16;15:855-65. doi: 10.2147/BCTT.S422025

Eriksson M, Andersson Galijatovic E, Schiel A, Brodtkorb T-H. The FINOSE collaboration – joint health technology assessment in the Nordics. Presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark.

Onukwugha E, Earnshaw S, Pizzi L, Shukla S. Professional competencies for health economics and outcomes research – 2023 update to the ISPOR Competencies Framework. Presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark.

Dolin P, Kielar D, Shavit A, Keogh K, Rowell J, Edmonds C, Meyers J, Esterberg L, Nham T, Chen S. Diagnosis pathways in patients with eosinophilic granulomatosis with polyangiitis (EGPA): a retrospective analysis of US health insurance claims data. Poster presented at the American College of Rheumatology (ACR) Convergence 2023; November 13, 2023. San Diego, CA. Previously presented at the Eastern Pulmonary Conference.

Dolin P, Kielar D, Shavit A, Keogh K, Rowell J, Edmonds C, Meyers J, Esterberg L, Nham T, Chen S. Treatment patterns for eosinophilic granulomatosis with polyangiitis (EGPA): a retrospective analysis of US health insurance claims data. Poster presented at the American College of Rheumatology (ACR) Convergence 2023; November 13, 2023. San Diego, CA.

Dolin P, Kielar D, Shavit A, Keogh K, Rowell J, Edmonds C, Meyers J, Esterberg L, Nham T, Chen S. Disease burden or eosinophilic granulomatosis with polyangiitis (EGPA): a retrospective analysis of US health insurance claims data. Poster presented at the American College of Rheumatology (ACR) Convergence 2023; November 13, 2023. San Diego, CA.

Brodtkorb T-H, Brogan A, Davis A, Earnshaw S. Budget impact analysis II: applications and design issues. Presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. Previously presented at the 2022 Virtual ISPOR Short Course Program.

Earnshaw S, Brodtkorb T-H, Mullins D. Budget impact analysis I: a 6-step approach. Presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. Previously presented at the ISPOR 18th Annual European Congress.

Castro E, Schlack K, Niyazov A, Houghton K, Kirker M, Derrien Ansquer V, Bello F, Jones RJ. Impact of treatment (tx) intensification on tx patterns and outcomes in the real world (rw) among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in Europe. Poster presented at the 15th European Multidisciplinary Congress on Urological Cancers; November 2, 2023. Marseille, France.

Curtis R, Decker-Palmer M, Wilson MR, McDade CL, Lin CW, Wallick C, Ko RH. Cost-effectiveness of emicizumab vs efanesoctocog alfa, standard half life (SHL) and other extended half life (EHL) FVIII products for prophylaxis in people with severe hemophilia a without inhibitors. Poster presented at the 65th ASH Annual Meeting & Exposition 2023; December 11, 2023. San Diego, CA. [abstract] Blood. 2023 Nov; 142(Supplement 1):5053-4. doi: 10.1182/blood-2023-181062

Wolf J, Souquet PJ, Goto K, Cortot A, Baik C, Heist R, Kim TM, Han JY, Neal JW, Mansfield AS, Gilloteau I, Nwama N, Waldron-Lynch M, Davis KL, Giovannini M, Awad MM. Improved survival outcomes in patients with MET-dysregulated advanced NSCLC treated with MET inhibitors: results of a multinational retrospective chart review. Clin Lung Cancer. 2023 Nov;24(7):641-650.e. doi: 10.1016/j.cllc.2023.08.011

Salem A, La EM, Curran D, Patterson BJ, Carrico J, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States. Pharmacoecon Open. 2023 Nov;7(6):975-85. doi: 10.1007/s41669-023-00438-7

Calvert ML, Korgaonkar S, Ramachandran S, Sarver DE. Follow-up care after maltreatment: sociodemographic associations with timeliness in a southern state. Child Maltreat. 2023 Nov;28(4):634-47. doi: 10.1177/10775595221134155.

Handels R, Wimo A, Skoldunger A, Tate A, Winblad B, Silvertand D, Nguyen L, Jonsson L, Grimm S, Aye S, Herring W. Open-source model framework for health-economic evaluation of early treatment in Alzheimer's disease. Presented at the ISPOR Europe 2023; November 2023. Copenhagen, Denmark.

Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24

Choi KY, Hao Q, Carlisle K, Hollenbeak CS, Lai SY. Cost-effectiveness of [99mTc]tilmanocept relative to [99mTc]sulfur colloid for sentinel lymph node biopsy in early stage oral cavity cancer. Ann Surg Oncol. 2023 Nov 1;30(12):7689-98. doi: 10.1245/s10434-023-13937-y

Hartley L, Harold S, Hawe E. The efficacy, safety, and immunogenicity of plague vaccines: a systematic literature review. CRIMMU. 2023 Nov 1;4:100072. doi: 10.1016/j.crimmu.2023.100072

Earnshaw S. Budget impact analysis: a 6-step approach. Presented at the UNC School of Pharmacy AMCP P&T Bootcamp event; October 25, 2023. Chapel Hill, NC.

Earnshaw S. Health economics and outcomes research. Presented at NC State Industrial Engineering course; October 25, 2023. Raleigh NC.

Ferguson JH, Fox L, Cox AJ. How can the underrepresentation curriculum increase representation in our communities? 2023.

Morris MJ, Armstrong AJ, Chi K, de Bono J, Herrmann K, Krause B, Rahbar K, Sartor O, Tagawa ST, Nagarajah J, Wei XX, Nordquist LT, Koshkin VS, Saad F, Vickers A, Ghouse R, Wu J, Mirante O, Fizazi K. Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer. Poster presented at the ESMO Congress 2023; October 22, 2023. Madrid, Spain.

Weber JS, Haque W, Markovic SN, Salama AKS, Mehmi I, Sullivan RJ, Najjar YG, Van Akkool A, Menzies A, Long G, Taylor AM, Haanen J, Zijlker L, Davis KL, Karanth S, Shah RM, Connolly L, Norton D. Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600–mutated stage III/IV melanoma. Poster presented at the ESMO Congress 2023; October 22, 2023. Madrid, Spain.

Brufsky A, Kwan ML, Sandin R, Karanth S, Makari D, Stergiopoulos S, Goyal R. Breast cancer specific survival (BCSS) in HR+/HER2- metastatic breast cancer (mBC) from 2010 to 2019. Poster presented at the ESMO Congress 2023; October 21, 2023. Madrid, Spain.

Howerton E, Dahlin K, Edholm CJ, Fox L, Reynolds M, Hollingsworth B, Lytle G, Walker M, Blackwood J, Lenhart S. The effect of governance structures on optimal control of two-patch epidemic models. J Math Biol. 2023 Oct 20;87(5):74. doi: 10.1007/s00285-023-02001-8

Khurana N, Hicks KA, Carrico J, Jacobson E, Farnham PG. Modeling the impact of injectable versus oral pre-exposure prophylaxis (PrEP) on HIV incidence and cost outcomes in the United States. Presentation to be given at the 2023 INFORMS Annual Meeting; October 16, 2023. Phoenix, AR.